AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

HIKMA Pharmaceuticals PLC

Director's Dealing Jan 18, 2023

4841_dirs_2023-01-18_e0a476a6-478e-4841-9a74-0b80fc3b90ef.html

Director's Dealing

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 1286N

Hikma Pharmaceuticals Plc

18 January 2023

Notification and public disclosure of transactions by persons discharging managerial responsibilities

1 Details of the person discharging managerial responsibilities / person closely associated
a) Name Deneen Vojta
2 Reason for the notification
a) Position/status Non-Executive Director
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification code Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083
b) Nature of the transaction Market purchase of 1000 Ordinary Shares
c) Price(s) and volume(s) Price(s): £17.02676

Volume(s):1000
d) Aggregated information

-       Volume



-       Price

-       Total
1000

£17.02676

£17,026.76
e) Date of the transaction 17 January 2023
f) Place of the transaction London Stock Exchange (XLON)

Helen Middlemist, Deputy Company Secretary, responsible for releasing this announcement

+44 (0) 20 7399 2760

18 January 2023

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBGGDBGBBDGXI

Talk to a Data Expert

Have a question? We'll get back to you promptly.